BiotechTube

Roxadustat + Epoetin Alfa

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia in Incident Dialysis Patients

Conditions

Anemia in Incident Dialysis Patients

Trial Timeline

Feb 11, 2014 → Sep 21, 2018

NCT ID
NCT02052310

About Roxadustat + Epoetin Alfa

Roxadustat + Epoetin Alfa is a phase 3 stage product being developed by Astellas Pharma for Anemia in Incident Dialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT02052310. Target conditions include Anemia in Incident Dialysis Patients.

What happened to similar drugs?

20 of 20 similar drugs in Anemia in Incident Dialysis Patients were approved

Approved (20) Terminated (5) Active (0)
✅Aranesp®AmgenApproved
✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved
✅Epoetin AlfaJohnson & JohnsonApproved
✅Roxadustat + rHuEPOAstraZenecaApproved
✅ICL670 + Chelation + No chelationNovartisApproved
✅cera, darbepoetin, epoetin-beta + ESARocheApproved
✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02052310Phase 3Completed
NCT01147666Phase 2Completed

Competing Products

20 competing products in Anemia in Incident Dialysis Patients

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40